Tricuspid valve replacement: porcine bioprostheses and mechanical prostheses. 1995

A I Munro, and W R Jamieson, and G F Tyers, and E Germann
Division of Cardiovascular and Thoracic Surgery, University of British Columbia, Vancouver, Canada.

The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age of 55.4 +/- 13.8 years. Bioprostheses (mean patient age, 55.9 +/- 14.1 years) were used in 83 operations and mechanical prostheses (mean patient age, 52.1 +/- 11.9 years) were used in 14 operations. There were 30 isolated tricuspid valve replacements and 67 tricuspid valve replacements incorporated in multiple valve replacements. The total cumulative follow-up was 360 patient-years (bioprostheses, 321 years; mechanical prostheses, 39 years) (96.8% complete). The mean follow-up was 3.7 years (bioprostheses, 3.9 years; mechanical prostheses, 2.8 years) (p = not significant). The early mortality was 14.4% (bioprostheses, 14.5%; mechanical prostheses, 14.3%) (p = not significant) (isolated replacement, 13.3%; multiple replacement, 14.9%). The late mortality was 9.2% per patient-year (isolated replacement, 12.2% per patient-year; multiple replacement, 7.9% per patient-year). The freedom from structural valve deterioration at 5 and 7 years was 100% for mechanical prostheses and 97.1% +/- 2.9% for bioprostheses (p = not significant). For isolated tricuspid valve replacement, the freedom from structural valve deterioration for bioprostheses was 90.9% +/- 8.7% at 5 years and at 7 years (p = not significant). For the mechanical prostheses, the freedom was 100%.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012086 Reoperation A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery. Revision, Joint,Revision, Surgical,Surgery, Repeat,Surgical Revision,Repeat Surgery,Revision Surgery,Joint Revision,Revision Surgeries,Surgery, Revision
D005260 Female Females
D006350 Heart Valve Prosthesis A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material. Prosthesis, Heart Valve,Cardiac Valve Prosthesis,Cardiac Valve Prostheses,Heart Valve Prostheses,Prostheses, Cardiac Valve,Prostheses, Heart Valve,Prosthesis, Cardiac Valve,Valve Prostheses, Cardiac,Valve Prostheses, Heart,Valve Prosthesis, Cardiac,Valve Prosthesis, Heart
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000206 Actuarial Analysis The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs. Analysis, Actuarial,Actuarial Analyses,Analyses, Actuarial
D001705 Bioprosthesis Prosthesis, usually heart valve, composed of biological material and whose durability depends upon the stability of the material after pretreatment, rather than regeneration by host cell ingrowth. Durability is achieved 1, mechanically by the interposition of a cloth, usually polytetrafluoroethylene, between the host and the graft, and 2, chemically by stabilization of the tissue by intermolecular linking, usually with glutaraldehyde, after removal of antigenic components, or the use of reconstituted and restructured biopolymers. Glutaraldehyde-Stabilized Grafts,Heterograft Bioprosthesis,Porcine Xenograft Bioprosthesis,Xenograft Bioprosthesis,Bioprostheses,Bioprostheses, Heterograft,Bioprostheses, Porcine Xenograft,Bioprostheses, Xenograft,Bioprosthesis, Heterograft,Bioprosthesis, Porcine Xenograft,Bioprosthesis, Xenograft,Glutaraldehyde Stabilized Grafts,Glutaraldehyde-Stabilized Graft,Graft, Glutaraldehyde-Stabilized,Grafts, Glutaraldehyde-Stabilized,Heterograft Bioprostheses,Porcine Xenograft Bioprostheses,Xenograft Bioprostheses,Xenograft Bioprostheses, Porcine,Xenograft Bioprosthesis, Porcine
D013927 Thrombosis Formation and development of a thrombus or blood clot in BLOOD VESSELS. Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses
D014261 Tricuspid Valve The valve consisting of three cusps situated between the right atrium and right ventricle of the heart. Tricuspid Valves,Valve, Tricuspid,Valves, Tricuspid

Related Publications

A I Munro, and W R Jamieson, and G F Tyers, and E Germann
June 1995, The Journal of thoracic and cardiovascular surgery,
A I Munro, and W R Jamieson, and G F Tyers, and E Germann
April 2000, The Annals of thoracic surgery,
A I Munro, and W R Jamieson, and G F Tyers, and E Germann
June 2005, The Thoracic and cardiovascular surgeon,
A I Munro, and W R Jamieson, and G F Tyers, and E Germann
November 1999, The Journal of heart valve disease,
A I Munro, and W R Jamieson, and G F Tyers, and E Germann
January 2014, Circulation journal : official journal of the Japanese Circulation Society,
A I Munro, and W R Jamieson, and G F Tyers, and E Germann
January 1991, The American journal of cardiology,
A I Munro, and W R Jamieson, and G F Tyers, and E Germann
March 2010, The Journal of heart valve disease,
A I Munro, and W R Jamieson, and G F Tyers, and E Germann
January 1988, ASAIO transactions,
A I Munro, and W R Jamieson, and G F Tyers, and E Germann
March 2006, The Annals of thoracic surgery,
A I Munro, and W R Jamieson, and G F Tyers, and E Germann
April 2006, The Journal of cardiovascular surgery,
Copied contents to your clipboard!